Minhtruong Tong Lai, MD
Critical Care (Intensivists) · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 2
- 2 carriers
- Offices
- 3
Offices
3 locations · University Healthcare Alliance · Sutter Bay Medical Foundation
Hospitals listed: Good Samaritan Hospital. That is not proof they admit you there this week.
Plans that list them
2 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Lai’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
2 of 2 plans
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A87630 · Current
Licensed to practise in California · since 2004 · expires 2028-02-29 · University of California, Davis School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$140,849
Medicare paid this office $140,849 for 413 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 236 | $66,694 | $114 |
| Critical care, first 30-74 minutes | 91 | $30,309 | $186 |
| New patient visit (45+ min) | 84 | $12,899 | $154 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 54 | $11,187 | $107 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,427 | $156 |
See all 9 services
| Return visit (30+ min) | 236 | $66,694 | $114 |
| Critical care, first 30-74 minutes | 91 | $30,309 | $186 |
| New patient visit (45+ min) | 84 | $12,899 | $154 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 54 | $11,187 | $107 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,427 | $156 |
| Test to examine how well the lungs exchange gases | 56 | $3,340 | $59 |
| Test to determine lung volumes using sensors | 56 | $3,321 | $58 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 56 | $2,202 | $39 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 58 | $892 | $15 |
Who their Medicare patients are
413 Original Medicare patients in 2024. Average age 78 · Under 65 3% · 85 and older 23% · Women 60% · Also on Medicaid 16% · Health risk score 2.03. At or below the middle of the specialty; the typical critical care (intensivists) clinician is at 2.58.
Conditions among them: High blood pressure 75% · COPD 47% · Coronary heart disease 42% · Diabetes 41% · Heart failure 39% · Atrial fibrillation 37% · Chronic kidney disease 32% · Cancer 24% · Depression 19% · Stroke 18% · Dementia 17%.
The office billed $736,818, Medicare allowed $185,631 and paid $140,849; for 1,254 services of 27 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 413 | 1,254 | 78 | 2.03 | $736,818 | $140,849 |
| 2023 | 411 | 1,442 | 79 | 2.03 | $838,016 | $185,998 |
| 2022 | 473 | 1,685 | 79 | 1.91 | $1,000,088 | $224,565 |
| 2021 | 508 | 2,052 | 78 | 1.93 | $1,131,164 | $274,362 |
| 2020 | 493 | 1,948 | 78 | 2.27 | $947,537 | $248,180 |
| 2019 | 637 | 2,604 | 78 | 2.36 | $1,154,181 | $301,660 |
| 2018 | 563 | 1,943 | 78 | 2.23 | $912,930 | $238,704 |
| 2017 | 513 | 1,772 | 77 | 2.25 | $710,228 | $200,787 |
| 2016 | 642 | 2,450 | 77 | 2.33 | $626,108 | $250,766 |
| 2015 | 598 | 2,618 | 76 | 2.21 | $656,853 | $274,419 |
| 2014 | 575 | 2,610 | 76 | 2.16 | $656,192 | $277,613 |
| 2013 | 463 | 2,195 | 76 | 2.07 | $531,191 | $216,763 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Critical care, first 30-74 minutes | 118 | $69,619 | $190 |
| Return visit (30+ min) | 227 | $57,933 | $116 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 92 | $30,052 | $110 |
| New patient visit (45+ min) | 55 | $8,440 | $153 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,359 | $153 |
| Test to examine how well the lungs exchange gases | 46 | $2,754 | $60 |
| Test to determine lung volumes using sensors | 46 | $2,598 | $56 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 45 | $1,791 | $40 |
| Critical care, each additional 30 minutes | 11 | $1,254 | $96 |
2022: 13 services
| Critical care, first 30-74 minutes | 162 | $95,171 | $199 |
| Return visit (30+ min) | 223 | $58,085 | $120 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 138 | $41,816 | $96 |
| New patient visit (45+ min) | 47 | $7,342 | $156 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,558 | $183 |
| Long return visit (40+ min) | 12 | $2,105 | $175 |
| Test to examine how well the lungs exchange gases | 32 | $1,991 | $62 |
| Test to determine lung volumes using sensors | 32 | $1,823 | $57 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,715 | $122 |
| Critical care, each additional 30 minutes | 15 | $1,571 | $98 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $1,298 | $87 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 32 | $1,295 | $40 |
| Needle biopsy of windpipe cartilage, airway, and/or lung using an endoscope | 12 | $1,189 | $99 |
2021: 11 services
| Critical care, first 30-74 minutes | 194 | $117,383 | $204 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 198 | $58,845 | $96 |
| Return visit (30+ min) | 200 | $52,064 | $119 |
| New patient visit (45+ min) | 76 | $11,922 | $157 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 46 | $8,471 | $184 |
| Telephone medical discussion with physician, 21-30 minutes | 56 | $7,264 | $91 |
| Test to examine how well the lungs exchange gases | 48 | $2,946 | $61 |
| Test to determine lung volumes using sensors | 48 | $2,694 | $56 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 45 | $2,116 | $47 |
| Long return visit (40+ min) | 11 | $1,986 | $181 |
| Needle biopsy of windpipe cartilage, airway, and/or lung using an endoscope | 11 | $1,296 | $118 |
2020: 16 services
| Critical care, first 30-74 minutes | 216 | $109,034 | $205 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 212 | $65,590 | $98 |
| Return visit (30+ min) | 150 | $26,871 | $97 |
| Telephone medical discussion with physician, 21-30 minutes | 59 | $10,110 | $109 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 49 | $9,627 | $189 |
| New patient visit (45+ min) | 53 | $8,445 | $159 |
| Long return visit (40+ min) | 21 | $2,853 | $136 |
| Critical care, each additional 30 minutes | 20 | $2,156 | $103 |
| Test to examine how well the lungs exchange gases | 26 | $1,515 | $58 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 26 | $1,501 | $58 |
| Test to determine lung volumes using sensors | 26 | $1,467 | $56 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 18 | $1,389 | $77 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 13 | $1,338 | $103 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,077 | $67 |
| Ultrasonic guidance for blood vessel access | 19 | $252 | $13 |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 14 | $1 | None |
2019: 15 services
| Critical care, first 30-74 minutes | 240 | $115,508 | $199 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 298 | $88,451 | $95 |
| Return visit (30+ min) | 220 | $47,922 | $96 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 95 | $17,506 | $184 |
| New patient visit (45+ min) | 60 | $8,601 | $143 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 45 | $4,838 | $66 |
| Critical care, each additional 30 minutes | 25 | $2,990 | $100 |
| Long return visit (40+ min) | 17 | $2,323 | $129 |
| Test to examine how well the lungs exchange gases | 38 | $2,233 | $59 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 35 | $2,199 | $63 |
| Test to determine lung volumes using sensors | 38 | $2,153 | $57 |
| Hospital discharge day management, more than 30 minutes | 20 | $1,991 | $100 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 19 | $1,526 | $76 |
| Ultrasonic guidance for blood vessel access | 18 | $262 | $13 |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 38 | $4 | None |
2018: 13 services
| Critical care, first 30-74 minutes | 254 | $105,045 | $196 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 237 | $60,435 | $93 |
| Return visit (30+ min) | 178 | $38,891 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 68 | $12,734 | $182 |
| New patient visit (45+ min) | 46 | $7,044 | $153 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 37 | $3,488 | $65 |
| Critical care, each additional 30 minutes | 17 | $1,962 | $98 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 18 | $1,779 | $89 |
| Hospital discharge day management, more than 30 minutes | 13 | $1,284 | $99 |
| Test to examine how well the lungs exchange gases | 18 | $1,030 | $57 |
| Test to determine lung volumes using sensors | 18 | $1,027 | $57 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 14 | $840 | $60 |
| Ultrasonic guidance for blood vessel access | 11 | $167 | $13 |
2017: 13 services
| Critical care, first 30-74 minutes | 212 | $80,202 | $188 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 181 | $47,072 | $90 |
| Return visit (30+ min) | 181 | $39,496 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 74 | $8,897 | $61 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 35 | $5,724 | $164 |
| New patient visit (45+ min) | 40 | $5,312 | $133 |
| Long return visit (40+ min) | 11 | $1,395 | $127 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 12 | $1,233 | $103 |
| Critical care, each additional 30 minutes | 11 | $1,145 | $95 |
| Insertion of artery tube for blood sampling or infusion through skin | 11 | $476 | $43 |
| Test to measure resistance of the airways and lungs to differing frequencies | 12 | $134 | $11 |
| Test to determine lung volumes using gas dilution or washout | 12 | $129 | $11 |
| Test to examine how well the lungs exchange gases | 12 | $96 | $8 |
2016: 17 services
| Critical care, first 30-74 minutes | 243 | $104,942 | $185 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 237 | $49,552 | $87 |
| Return visit (30+ min) | 215 | $46,786 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 136 | $15,070 | $61 |
| New patient visit (45+ min) | 86 | $12,303 | $143 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 37 | $6,448 | $170 |
| Insertion of artery tube for blood sampling or infusion through skin | 41 | $2,142 | $43 |
| Hospital discharge day management, more than 30 minutes | 15 | $1,494 | $93 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 12 | $1,280 | $91 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 12 | $920 | $77 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 51 | $614 | $11 |
| Test to determine lung volumes using gas dilution or washout | 53 | $598 | $10 |
| Test to examine how well the lungs exchange gases | 53 | $442 | $8 |
| Test to determine lung volumes using gas dilution or washout | 22 | $234 | $11 |
| Test to examine how well the lungs exchange gases | 22 | $173 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 22 | $150 | $7 |
| Test to measure expiratory airflow and volume | 17 | $124 | $7 |
2015: 15 services
| Critical care, first 30-74 minutes | 196 | $102,323 | $193 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 253 | $59,041 | $91 |
| Return visit (30+ min) | 199 | $44,011 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 191 | $28,337 | $64 |
| New patient visit (45+ min) | 88 | $12,594 | $143 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 65 | $11,573 | $178 |
| Hospital discharge day management, more than 30 minutes | 37 | $3,657 | $96 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 18 | $1,883 | $105 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 51 | $649 | $12 |
| Test to determine lung volumes using gas dilution or washout | 52 | $623 | $11 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 15 | $548 | $34 |
| Test to examine how well the lungs exchange gases | 52 | $460 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 17 | $197 | $12 |
| Test to determine lung volumes using gas dilution or washout | 17 | $186 | $11 |
| Test to examine how well the lungs exchange gases | 17 | $137 | $8 |
2014: 16 services
| Critical care, first 30-74 minutes | 198 | $101,494 | $195 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 252 | $68,766 | $92 |
| Return visit (30+ min) | 154 | $35,156 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 187 | $29,335 | $64 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 76 | $13,930 | $179 |
| New patient visit (45+ min) | 79 | $11,482 | $145 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 54 | $5,870 | $107 |
| Hospital discharge day management, more than 30 minutes | 36 | $3,475 | $97 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 36 | $1,284 | $35 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 32 | $402 | $11 |
| Test to determine lung volumes using gas dilution or washout | 30 | $356 | $11 |
| Test to examine how well the lungs exchange gases | 31 | $271 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 16 | $188 | $12 |
| Test to determine lung volumes using gas dilution or washout | 16 | $177 | $11 |
| Test to examine how well the lungs exchange gases | 16 | $131 | $8 |
| Test to measure expiratory airflow and volume | 11 | $83 | $8 |
2013: 17 services
| Critical care, first 30-74 minutes | 154 | $77,465 | $190 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 189 | $43,657 | $89 |
| Return visit (30+ min) | 137 | $32,928 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 153 | $25,306 | $62 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 78 | $13,828 | $175 |
| New patient visit (45+ min) | 44 | $6,307 | $143 |
| Hospital discharge day management, more than 30 minutes | 36 | $3,403 | $95 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 29 | $3,014 | $104 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 49 | $1,820 | $34 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 12 | $936 | $72 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 44 | $485 | $11 |
| Test to determine lung volumes using gas dilution or washout | 42 | $464 | $11 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 32 | $379 | $11 |
| Test to examine how well the lungs exchange gases | 42 | $341 | $8 |
| Test to determine lung volumes using gas dilution or washout | 27 | $311 | $12 |
| Test to examine how well the lungs exchange gases | 28 | $237 | $8 |
| Ultrasonic guidance for blood vessel access | 16 | $204 | $13 |
Medicaid work
$11,581 in 2018
Medicaid paid $11,581 for 23 billed services this clinician did in 2018, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 23 | $11,581 |
| 2018 | 23 | 1 | 15 | $11,581 |
Drugs they prescribed that Part D paid
$357,193
Pharmacies billed $357,193 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 896) in 2024. At or below the middle of the specialty; the typical critical care (intensivists) clinician is at 0%.
0 generic and 511 brand-name prescriptions · $357,193 in drug cost · 38 antibiotic prescriptions to 20 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Trelegy Ellipta | 175 | $135,687 | $775 |
| Dupixent | 14 | $53,019 | $3,787 |
| Breztri Aerosphere | 33 | $42,613 | $1,291 |
| Breo Ellipta | 39 | $18,838 | $483 |
| Anoro Ellipta | 34 | $17,535 | $516 |
See all 20 drugs
| Trelegy Ellipta | 175 | $135,687 | $775 |
| Dupixent | 14 | $53,019 | $3,787 |
| Breztri Aerosphere | 33 | $42,613 | $1,291 |
| Breo Ellipta | 39 | $18,838 | $483 |
| Anoro Ellipta | 34 | $17,535 | $516 |
| Eliquis | 12 | $11,544 | $962 |
| Spiriva Respimat | 16 | $9,291 | $581 |
| Advair Hfa | 13 | $7,902 | $608 |
| Arnuity Ellipta | 22 | $7,097 | $323 |
| Wixela Inhub | 28 | $5,691 | $203 |
| Symbicort | 18 | $5,504 | $306 |
| Dulera | 11 | $5,279 | $480 |
| Roflumilast | 19 | $4,633 | $244 |
| Albuterol Sulfate Hfa | 109 | $3,877 | $36 |
| Mycophenolate Mofetil | 14 | $1,592 | $114 |
| Ventolin Hfa | 17 | $1,522 | $90 |
| Prednisone | 146 | $893 | $6 |
| Azithromycin | 23 | $324 | $14 |
| Montelukast | 13 | $244 | $19 |
| Bumetanide | 16 | $149 | $9 |
Year by year
| 2024 | 896 | 174 | 0% (0) | 57% | $357,193 |
| 2023 | 835 | 154 | 0% (0) | 63% | $444,105 |
| 2022 | 891 | 155 | None | 70% | $564,462 |
| 2021 | 865 | 147 | 0% (0) | 70% | $496,049 |
| 2020 | 824 | 133 | None | 70% | $521,948 |
| 2019 | 877 | 140 | None | 68% | $412,151 |
| 2018 | 727 | 102 | 0% (0) | 66% | $275,815 |
| 2017 | 693 | 111 | 0% (0) | 63% | $289,854 |
| 2016 | 634 | 123 | None | 59% | $227,215 |
| 2015 | 722 | 124 | None | 59% | $225,058 |
| 2014 | 603 | 116 | None | 64% | $111,634 |
| 2013 | 489 | 83 | 0% (0) | 63% | $72,601 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Trelegy Ellipta | 159 | $131,701 | $828 |
| Breztri Aerosphere | 39 | $36,453 | $935 |
| Spiriva Respimat | 29 | $20,503 | $707 |
| Symbicort | 31 | $19,914 | $642 |
| Breo Ellipta | 31 | $17,775 | $573 |
| Anoro Ellipta | 26 | $16,042 | $617 |
| Advair Diskus | 15 | $9,528 | $635 |
| Arnuity Ellipta | 15 | $5,717 | $381 |
| Albuterol Sulfate Hfa | 95 | $3,335 | $35 |
| Eszopiclone | 11 | $2,905 | $264 |
| Ventolin Hfa | 29 | $2,453 | $85 |
| Prednisone | 137 | $938 | $7 |
| Montelukast | 17 | $242 | $14 |
2022: 20 drugs
| Ofev | 13 | $161,725 | $12,440 |
| Trelegy Ellipta | 147 | $115,690 | $787 |
| Breo Ellipta | 90 | $43,818 | $487 |
| Symbicort | 38 | $23,575 | $620 |
| Breztri Aerosphere | 20 | $23,549 | $1,177 |
| Spiriva Respimat | 32 | $20,218 | $632 |
| Incruse Ellipta | 27 | $17,777 | $658 |
| Anoro Ellipta | 31 | $17,594 | $568 |
| Spiriva Handihaler | 16 | $10,610 | $663 |
| Stiolto Respimat | 21 | $10,174 | $484 |
| Budesonide-Formoterol | 13 | $6,231 | $479 |
| Flovent Hfa | 11 | $4,983 | $453 |
| Advair Diskus | 11 | $4,750 | $432 |
| Albuterol Sulfate Hfa | 70 | $4,614 | $66 |
| Eszopiclone | 13 | $3,420 | $263 |
| Wixela Inhub | 12 | $3,137 | $261 |
| Ventolin Hfa | 34 | $2,032 | $60 |
| Proair Hfa | 13 | $1,034 | $80 |
| Prednisone | 95 | $620 | $7 |
| Montelukast | 24 | $292 | $12 |
2021: 21 drugs
| Ofev | 11 | $130,807 | $11,892 |
| Trelegy Ellipta | 119 | $86,915 | $730 |
| Symbicort | 59 | $41,310 | $700 |
| Breo Ellipta | 75 | $35,634 | $475 |
| Anoro Ellipta | 33 | $19,016 | $576 |
| Spiriva | 18 | $15,661 | $870 |
| Incruse Ellipta | 25 | $15,374 | $615 |
| Spiriva Respimat | 28 | $14,861 | $531 |
| Stiolto Respimat | 28 | $12,697 | $453 |
| Advair Diskus | 16 | $7,347 | $459 |
| Wixela Inhub | 27 | $7,223 | $268 |
| Albuterol Sulfate Hfa | 84 | $4,812 | $57 |
| Qvar Redihaler | 13 | $3,982 | $306 |
| Dulera | 12 | $3,871 | $323 |
| Flovent Diskus | 11 | $3,126 | $284 |
| Proair Hfa | 20 | $1,463 | $73 |
| Ventolin Hfa | 14 | $827 | $59 |
| Prednisone | 90 | $727 | $8 |
| Montelukast | 31 | $575 | $19 |
| Azithromycin | 11 | $269 | $24 |
| Promethazine-Codeine | 11 | $131 | $12 |
2020: 24 drugs
| Esbriet | 18 | $173,813 | $9,656 |
| Symbicort | 92 | $64,452 | $701 |
| Trelegy Ellipta | 38 | $29,879 | $786 |
| Breo Ellipta | 52 | $24,325 | $468 |
| Incruse Ellipta | 34 | $18,975 | $558 |
| Spiriva | 21 | $18,256 | $869 |
| Anoro Ellipta | 36 | $15,523 | $431 |
| Stiolto Respimat | 26 | $11,312 | $435 |
| Combivent Respimat | 11 | $7,230 | $657 |
| Advair Diskus | 14 | $5,837 | $417 |
| Wixela Inhub | 14 | $5,292 | $378 |
| Dulera | 15 | $4,730 | $315 |
| Qvar Redihaler | 14 | $4,573 | $327 |
| Albuterol Sulfate Hfa | 70 | $4,405 | $63 |
| Flovent Diskus | 13 | $3,554 | $273 |
| Asmanex Hfa | 12 | $2,647 | $221 |
| Proair Hfa | 30 | $2,400 | $80 |
| Ventolin Hfa | 31 | $1,907 | $62 |
| Prednisone | 114 | $799 | $7 |
| Montelukast | 18 | $367 | $20 |
| Fluticasone Propionate | 15 | $316 | $21 |
| Azithromycin | 13 | $277 | $21 |
| Eszopiclone | 12 | $199 | $17 |
| Promethazine-Codeine | 12 | $137 | $11 |
2019: 22 drugs
| Esbriet | 18 | $152,647 | $8,480 |
| Symbicort | 132 | $74,601 | $565 |
| Spiriva | 29 | $19,542 | $674 |
| Spiriva Respimat | 34 | $18,404 | $541 |
| Combivent Respimat | 31 | $16,938 | $546 |
| Trelegy Ellipta | 23 | $16,679 | $725 |
| Breo Ellipta | 36 | $16,107 | $447 |
| Anoro Ellipta | 33 | $14,776 | $448 |
| Advair Diskus | 23 | $14,542 | $632 |
| Incruse Ellipta | 20 | $13,561 | $678 |
| Daliresp | 11 | $7,506 | $682 |
| Proair Hfa | 43 | $3,748 | $87 |
| Eszopiclone | 11 | $3,553 | $323 |
| Arnuity Ellipta | 17 | $3,228 | $190 |
| Flovent Diskus | 11 | $2,952 | $268 |
| Ventolin Hfa | 42 | $2,423 | $58 |
| Asmanex Hfa | 11 | $2,416 | $220 |
| Albuterol Sulfate Hfa | 20 | $1,873 | $94 |
| Prednisone | 139 | $1,308 | $9 |
| Montelukast | 19 | $467 | $25 |
| Azithromycin | 17 | $362 | $21 |
| Furosemide | 12 | $49 | $4 |
2018: 20 drugs
| Symbicort | 120 | $49,524 | $413 |
| Advair Diskus | 39 | $19,972 | $512 |
| Incruse Ellipta | 33 | $16,355 | $496 |
| Breo Ellipta | 32 | $14,216 | $444 |
| Spiriva | 18 | $11,354 | $631 |
| Spiriva Respimat | 18 | $10,476 | $582 |
| Anoro Ellipta | 21 | $9,282 | $442 |
| Daliresp | 16 | $9,093 | $568 |
| Combivent Respimat | 14 | $5,494 | $392 |
| Arnuity Ellipta | 24 | $4,973 | $207 |
| Proair Hfa | 39 | $3,635 | $93 |
| Flovent Diskus | 14 | $3,581 | $256 |
| Prednisone | 127 | $1,207 | $10 |
| Ventolin Hfa | 20 | $1,153 | $58 |
| Levalbuterol Tartrate Hfa | 12 | $658 | $55 |
| Eszopiclone | 11 | $575 | $52 |
| Montelukast | 30 | $465 | $15 |
| Azithromycin | 12 | $215 | $18 |
| Levothyroxine | 13 | $170 | $13 |
| Trazodone | 13 | $144 | $11 |
2017: 18 drugs
| Esbriet | 18 | $149,094 | $8,283 |
| Symbicort | 103 | $41,620 | $404 |
| Anoro Ellipta | 32 | $13,236 | $414 |
| Breo Ellipta | 35 | $13,181 | $377 |
| Combivent Respimat | 25 | $10,715 | $429 |
| Incruse Ellipta | 19 | $8,670 | $456 |
| Advair Diskus | 20 | $8,433 | $422 |
| Spiriva | 13 | $8,337 | $641 |
| Flovent Hfa | 12 | $5,487 | $457 |
| Proair Hfa | 59 | $4,073 | $69 |
| Arnuity Ellipta | 15 | $2,858 | $191 |
| Ventolin Hfa | 21 | $1,226 | $58 |
| Prednisone | 106 | $1,181 | $11 |
| Eszopiclone | 11 | $536 | $49 |
| Montelukast | 27 | $437 | $16 |
| Pramipexole Dihydrochloride | 15 | $149 | $10 |
| Trazodone | 17 | $98 | $6 |
| Furosemide | 15 | $81 | $5 |
2016: 17 drugs
| Esbriet | 13 | $103,202 | $7,939 |
| Symbicort | 80 | $33,615 | $420 |
| Advair Diskus | 28 | $16,078 | $574 |
| Combivent Respimat | 30 | $12,221 | $407 |
| Breo Ellipta | 29 | $12,114 | $418 |
| Spiriva | 12 | $8,930 | $744 |
| Flovent Hfa | 16 | $5,656 | $353 |
| Proair Hfa | 49 | $3,682 | $75 |
| Ventolin Hfa | 33 | $1,712 | $52 |
| Prednisone | 96 | $978 | $10 |
| Montelukast | 32 | $610 | $19 |
| Eszopiclone | 13 | $490 | $38 |
| Fluticasone Propionate | 17 | $295 | $17 |
| Levofloxacin | 14 | $239 | $17 |
| Azithromycin | 11 | $208 | $19 |
| Levothyroxine | 12 | $182 | $15 |
| Furosemide | 14 | $52 | $4 |
2015: 17 drugs
| Symbicort | 70 | $26,968 | $385 |
| Advair Diskus | 54 | $21,788 | $403 |
| Combivent Respimat | 48 | $16,269 | $339 |
| Spiriva | 30 | $14,267 | $476 |
| Flovent Hfa | 38 | $12,077 | $318 |
| Proair Hfa | 67 | $4,519 | $67 |
| Asmanex | 15 | $3,771 | $251 |
| Singulair | 12 | $2,412 | $201 |
| Eszopiclone | 12 | $749 | $62 |
| Montelukast | 27 | $612 | $23 |
| Prednisone | 62 | $425 | $7 |
| Fluticasone Propionate | 28 | $318 | $11 |
| Levofloxacin | 18 | $295 | $16 |
| Metoprolol | 12 | $266 | $22 |
| Azithromycin | 14 | $225 | $16 |
| Furosemide | 21 | $81 | $4 |
| Trazodone | 11 | $75 | $7 |
2014: 15 drugs
| Symbicort | 60 | $21,009 | $350 |
| Combivent Respimat | 64 | $19,363 | $303 |
| Flovent Hfa | 39 | $10,387 | $266 |
| Advair Diskus | 23 | $7,895 | $343 |
| Spiriva | 24 | $7,329 | $305 |
| Proair Hfa | 55 | $4,626 | $84 |
| Alvesco | 12 | $3,369 | $281 |
| Asmanex | 15 | $3,337 | $222 |
| Singulair | 12 | $2,257 | $188 |
| Prednisone | 51 | $637 | $12 |
| Montelukast | 27 | $620 | $23 |
| Azithromycin | 19 | $325 | $17 |
| Fluticasone Propionate | 16 | $212 | $13 |
| Levofloxacin | 11 | $101 | $9 |
| Pantoprazole | 11 | $75 | $7 |
2013: 17 drugs
| Flovent Hfa | 42 | $11,630 | $277 |
| Symbicort | 40 | $10,989 | $275 |
| Combivent Respimat | 34 | $10,188 | $300 |
| Advair Diskus | 19 | $6,664 | $351 |
| Combivent | 20 | $6,378 | $319 |
| Spiriva | 17 | $4,596 | $270 |
| Asmanex | 20 | $4,081 | $204 |
| Singulair | 13 | $2,245 | $173 |
| Proair Hfa | 31 | $2,101 | $68 |
| Nasonex | 11 | $1,518 | $138 |
| Montelukast | 29 | $654 | $23 |
| Fluticasone Propionate | 17 | $401 | $24 |
| Escitalopram | 12 | $284 | $24 |
| Azithromycin | 12 | $230 | $19 |
| Pantoprazole | 15 | $199 | $13 |
| Prednisone | 28 | $199 | $7 |
| Levothyroxine | 12 | $85 | $7 |
Money from drug and device companies
$889 in 2025
| 2025 | 9 | 47 | None | $889 |
| 2024 | 5 | 18 | None | $346 |
| 2023 | 5 | 9 | None | $248 |
| 2022 | 3 | 19 | None | $10,729 |
| 2021 | 2 | 3 | None | $75 |
| 2020 | 3 | 31 | None | $518 |
| 2019 | 7 | 28 | None | $642 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Fasenra | $374 | 14 payments
|
| GlaxoSmithKline | Nucala | $200 | 10 payments
|
| Genzyme | Dupixent | $104 | 5 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $66 | 3 payments
|
| Viatris Specialty | Yupelri | $42 | 2 payments
|
| Insmed | Arikayce | $39 | 2 payments
|
See all 39 published payments
| GlaxoSmithKline | Meals · 2025-12-18 | Nucala | $14 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-10 | Airsupra | $14 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-20 | Airsupra | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-13 | Fasenra | $14 |
| GlaxoSmithKline | Meals · 2025-11-06 | Nucala | $23 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-29 | Airsupra | $29 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-23 | Breztri | $34 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-17 | Tezspire | $30 |
| Genzyme | Meals · 2025-10-09 | Dupixent | $19 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-02 | Tezspire | $14 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-25 | Fasenra | $17 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-12 | Airsupra | $14 |
| Insmed | Education · 2025-09-10 | Brinsupri | $17 |
| Insmed | Meals · 2025-09-10 | Arikayce | $22 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-06 | Fasenra | $32 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-05 | Breztri | $34 |
| Genzyme | Meals · 2025-07-17 | Dupixent | $27 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-07-09 | Ofev | $18 |
| GlaxoSmithKline | Meals · 2025-06-24 | Nucala | $17 |
| Octapharma USA | Meals · 2025-06-19 | Balfaxar | $19 |
| Genzyme | Meals · 2025-06-12 | Dupixent | $15 |
| GlaxoSmithKline | Meals · 2025-06-11 | Trelegy Ellipta | $29 |
| GlaxoSmithKline | Meals · 2025-06-03 | Nucala | $14 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-03 | Airsupra | $18 |
| Genzyme | Meals · 2025-05-21 | Dupixent | $24 |
| GlaxoSmithKline | Meals · 2025-05-12 | Nucala | $20 |
| Viatris Specialty | Meals · 2025-05-06 | Yupelri | $21 |
| Philips North America | Meals · 2025-04-23 | Vest Therapy Und | $30 |
| GlaxoSmithKline | Meals · 2025-04-16 | Nucala | $23 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-27 | Airsupra | $30 |
| Viatris Specialty | Meals · 2025-03-12 | Yupelri | $21 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-03-11 | Ofev | $25 |
| GlaxoSmithKline | Meals · 2025-02-25 | Nucala | $3 |
| GlaxoSmithKline | Meals · 2025-02-25 | Nucala | $24 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-02-06 | Ofev | $24 |
| Electromed | Meals · 2025-01-30 | Smartvest | $14 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-28 | Fasenra | $69 |
| Genzyme | Meals · 2025-01-17 | Dupixent | $19 |
| GlaxoSmithKline | Meals · 2025-01-10 | Nucala | $33 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $346
| AstraZeneca Pharmaceuticals LP | Airsupra | $242 | 10 payments
|
| Amgen | Tezspire | $33 | 1 payment
|
| Philips North America | (8874) Incourage | $30 | 1 payment
|
| Genzyme | Dupixent | $26 | 1 payment
|
| Insmed | Arikayce | $16 | 1 payment
|
2023: $248
| AstraZeneca Pharmaceuticals LP | Airsupra | $90 | 4 payments
|
| Medtronic | Illumisite | $68 | 1 payment
|
| GlaxoSmithKline | Trelegy Ellipta | $51 | 2 payments
|
| Amgen | Tezspire | $20 | 1 payment
|
| Philips Electronics North America | (8874) Incourage | $20 | 1 payment
|
2022: $10,729
| Intuitive Surgical | Ion | $10,630 | 13 payments
|
| GlaxoSmithKline | Nucala | $72 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Breztri | $26 | 2 payments
|
2021: $75
| GlaxoSmithKline | Nucala | $46 | 2 payments
|
| Insmed | Arikayce | $29 | 1 payment
|
2020: $518
| GlaxoSmithKline | Anoro Ellipta | $343 | 23 payments
|
| Insmed | Arikayce | $131 | 6 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $44 | 2 payments
|
2019: $642
| GlaxoSmithKline | Nucala | $189 | 16 payments
|
| Abbott Laboratories | Heartmate 3 Left Ventricular Dev | $131 | 1 payment
|
| Merck Sharp & Dohme | Zerbaxa | $121 | 1 payment
|
| Insmed | Arikayce | $85 | 4 payments
|
| Genentech USA | Esbriet | $81 | 4 payments
|
| Boehringer Ingelheim Pharmaceuticals | Spiriva Respimat | $21 | 1 payment
|
| Mylan Specialty L.P. | Yupelri | $15 | 1 payment
|
Professional record
- NPI
- 1437204658
- Licence
- CA A87630California A87630: Current · expires 2028-02-29
- Trained
- University of California, Davis School of Medicine, 2002
- Group
- University Healthcare Alliance · Sutter Bay Medical Foundation
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RP1001X (207RP1001X); Internal medicine (207R00000X); Federal specialty code 207RC0200X (207RC0200X); Federal specialty code 2084A2900X (2084A2900X)
- Mailing address
- 2425 Samaritan Dr, San Jose, CA, 95124
- NPI first listed
- 2007-01-25
- NPI last updated
- 2024-07-03
- NPI record certified
- 2024-07-03
This is when the NPI record was last certified, not a medical board exam.